Aratana Therapeutics said Tuesday the U.S. Department of Agricultural granted conditional approval to a drug designed to treat T-cell lymphoma in dogs.
Aratana said it received conditional approval to market AT-005 because it has demonstrated that the drug is safe and it's reasonable to expect it is effective. The company said it is running additional studies to support the safety and effectiveness of AT-005.
The USDA cleared the company's drug AT-004, which treats canine B-cell lymphoma, in 2012. Novartis markets that drug.
Aratana Therapeutics Inc. shares closed at $18.21 on Monday.